Patents Assigned to Novo Nordisk A/S
  • Patent number: 11325983
    Abstract: The invention relates to a bispecific antibody comprising a first antigen-binding site capable of binding Factor VII(a) and a second antigen-binding site capable of binding TLT-1, pharmaceutical formulations comprising such bispecific antibodies and uses thereof.
    Type: Grant
    Filed: October 14, 2021
    Date of Patent: May 10, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Prafull S. Gandhi, Jens Breinholt, Henrik Oestergaard
  • Patent number: 11318191
    Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.1% (w/w) phenol and above 6.4 mg/ml sodium chloride, their preparation, kits comprising such compositions as well as uses thereof.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: May 3, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Dorthe Kot Engelund, Soeren Snitker, Andrew Mark Louw
  • Patent number: 11318251
    Abstract: A medication delivery device comprises an injection device having a reservoir comprising a medicament to be ejected, and a sensor arranged to detect an ejection of the medicament from the injection device, the sensor being arranged to output a signal comprising ejecting information, and a processor for collecting and storing the ejection information.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: May 3, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Dedenroth Miller, Christian Peter Enggaard, Preben Mikael Nielsen, Bodo von Muenchow
  • Patent number: 11318257
    Abstract: A drug delivery device comprising or adapted to receive a drug-filled cartridge, comprising a piston rod adapted to be rotated by a drive member to thereby move the piston rod distally during expelling, dose setting means allowing a user to simultaneously set a dose amount to be expelled, and a releasable locking mechanism adapted to rotationally lock the drive member relative to the housing during dose setting. The device further comprises release means actuatable between a dose setting mode and an expelling mode, wherein the locking mechanism is released when the release means is actuated from a dose setting mode to an expelling mode.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: May 3, 2022
    Assignee: Novo Nordisk A/S
    Inventor: Jesper Peter Windum
  • Patent number: 11311678
    Abstract: A sensor assembly comprising a first rotary sensor part having a plurality of individual electrically conducting code segments arranged in a circumferential pattern, and a plurality of electrically conducting reference segments between the code segments, and a second rotary sensor part arranged rotationally relative to the first part a plurality of contact structures, each contact structure being arranged to be in contact with either a code segment or a reference segment depending on the rotational position between the first and second rotary sensor part. The contact structures are configured to engage and connect to different sensor segments as the first and second rotary sensor part rotate relative to each, the created connections being indicative of a rotational position between the first and second rotary sensor part. For a given rotational position, at least one contact structure engages a code segment and at least one contact structure engages a reference segment.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: April 26, 2022
    Assignee: Novo Nordisk A/S
    Inventors: John Oestergaard Madsen, Steffen Mews, Jacob Sonnerup Moellebro, Lars Peter Klitmose
  • Patent number: 11311679
    Abstract: The present invention relates to a handheld mechanical injection device by which set doses of a liquid medicament can be injected from a medical reservoir. The medicament is expelled through an injection needle by release of a power reservoir in the device, the power reservoir being fully or partially released by actuation of a user operable release member being positioned at or near an upper end of the injection device, the upper end being that end of the injection device which is opposite the injection needle.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: April 26, 2022
    Assignee: Novo Nordisk A/S
    Inventor: Tom Hede Markussen
  • Patent number: 11298461
    Abstract: Systems and methods are provided for adjusting long acting insulin medicament dosages for a subject. A plurality of timestamped glucose measurements of the subject is obtained. A titration glucose level (246) is computed as a measure of central tendency (244, 268, 274) of a titration subset of small glucose measurements (240, 269, 273) identified within the timestamped glucose measurements, wherein the measure of central tendency represents a measure of small glucose measurements for the primary time window. A long acting insulin medicament dosage (216) is adjusted or maintained based upon the obtained titration glucose level (246).
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: April 12, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Tinna Bjoerk Aradottir, Henrik Bengtsson, Morten Lind Jensen, Pete Brockmeier
  • Patent number: 11292825
    Abstract: The invention relates to protein conjugates and in particular conjugates of more than two protein or polypeptides. The compounds include a trivalent linker moiety that enables efficient production of desired products.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: April 5, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Emiliano Clo, Mikael Kofod-Hansen, Henrik Sune Ramirez-Andersen, Nils Langeland Johansen
  • Patent number: 11295847
    Abstract: Systems and methods are provided for optimizing basal administration timing in a standing basal insulin regimen of a subject. The regimen specifies a total amount of basal insulin medicament, one or more basal injection event types for a recurring period, and an apportionment of the total amount of medicament between the injection event types. Time stamped glucose measurements of the subject are obtained over a past time course comprising a plurality of instances of the recurring period. When the glucose measurements satisfy a stop condition, a recommended adjustment is determined that comprises a change in the number of injection event types in the regimen and/or a change in the apportionment of insulin medicament between injection event types. The recommended adjustment is communicated to the subject for manual adjustment of the regimen, an insulin pen charged with delivering the regimen to the subject, or a health care practitioner associated with the subject.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: April 5, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Tinna Bjoerk Aradottir, Henrik Bengtsson, Pete Brockmeier, Jonas Kildegaard Pedersen
  • Patent number: 11291777
    Abstract: A needle cannula for an injection device, extends along a central axis and comprises: a) a skin piercing distal end (133b), b) a proximal end (133a) configured for penetrating a seal structure (102b) of a medicament container (102), and c) a sidewall extending between the skin piercing distal end (133b) and the proximal end (133a), wherein the proximal end (133a) is defined by an angled surface (134) pointing proximally, the angled surface (134) defining a leading portion (134.1) and a heel portion (134.2), and wherein the angled surface (134) comprises a surface portion (134a, 134b) at the heel portion (134.2) forming an angle (?1) between 50 to 75 degrees with respect to the central axis, and further comprises a surface portion (134c) at the leading portion (134.1) forming an angle (?2) between 60 to 85 degrees with respect to the central axis. An injection needle assembly for an injection device and an injection device comprising such assembly are further described.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: April 5, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Lene Westergaard Toennesen, Erik Pedersen, Ejnar Laustsen
  • Patent number: 11282598
    Abstract: Systems and methods for treating a subject are provided. A first dataset comprising timestamped autonomous glucose measurements of the subject over a first time course is obtained. A second dataset, associated with a standing insulin regimen for the subject over the first time course and comprising insulin medicament records, is also obtained. Each record comprises a timestamped injection event including an amount and type of insulin medicament injected into the subject by an insulin pen. The first and second datasets serve to calculate a glycaemic risk measure and an insulin sensitivity factor of the subject during the first time course, which are used to obtain a basal titration schedule and a fasting blood glucose profile model over a subsequent second time course for the subject. The model predicts the fasting blood glucose level of the subject based upon amounts of basal insulin medicament injected into the subject.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: March 22, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Brad Warren Van Orden, Jakob Oest Wielandt, Thomas Dedenroth Miller, Tinna Bjoerk Aradottir, Pete Brockmeier, Henrik Bengtsson
  • Patent number: 11279771
    Abstract: The application discloses bispecific TFPI antibodies that are capable of specifically and simultaneously binding two epitopes within TFPI (1-161). Such bispecific antibodies strongly enhance thrombin generation by neutralising TFPI, even where the concentration of TFPI is elevated. Bispecific antibodies of the invention or compositions comprising them may be used for the treatment of subjects with a coagulopathy.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: March 22, 2022
    Assignee: NOVO NORDISK A/S
    Inventors: Helle Heibroch Petersen, Berit Olsen Krogh, Jens Breinholt, Mikael Kofod-Hansen, Ida Hilden
  • Patent number: 11279745
    Abstract: The present invention relates to plasmids useful for prevention and/or delay of e.g. type 1 diabetes.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: March 22, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Jay Chaplin, Michael Wijaranakula
  • Patent number: 11278596
    Abstract: The present invention relates to insulin degludec for use in medicine.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: March 22, 2022
    Assignee: NOVO NORDISK A/S
    Inventors: Simon Skibsted, Kajsa Kvist
  • Patent number: 11273261
    Abstract: The present invention concerns a prefilled injection device having a container and a dose setting mechanism encapsulated inside a housing. The injection device incorporates an axial variable connection such that a distance between a distal end of a piston rod and a plunger is minimized preferably to zero.
    Type: Grant
    Filed: January 20, 2009
    Date of Patent: March 15, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Bo Radmer, Jakob Oest Wielandt, Frank Andreas Jespersen, Tom Hede Markussen, Jacob Kollerup Jensen
  • Patent number: 11274135
    Abstract: The invention relates to a derivative of a GLP-1 peptide, which peptide comprises a first K residue and a second K residue, at positions corresponding to position 26, and 34, respectively, of GLP-1(7-37) (SEQ ID NO:1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is Chem. 2: HOOC—C6H4—O—(CH2)y—CO—*, in which y is an integer in the range of 6-13; and the linker comprises Chem. 3a: *—NH—(CH2)q—CH[(CH2)w—NR1R2]—CO—*, wherein q is an integer in the range of 0-5, R1 and R2 independently represent *—H or *—CH3, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptide and linker intermediates.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: March 15, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Jacob Kofoed, Patrick W. Garibay
  • Patent number: 11274280
    Abstract: The present invention relates to generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors. The present invention also relates to functional beta cells produced by said methods and uses of said beta cells.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: March 15, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Nicolaj Stroeyer Christophersen, Ulrik Doehn, Mattias Hansson
  • Patent number: 11260108
    Abstract: The invention relates to MIC-1 compounds for use in the prevention and/or treatment of obesity, wherein the MIC-1 compounds is administered simultaneously, separately or sequentially with a GLP-1 compound.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: March 1, 2022
    Assignee: Novo Nordisk A/S
    Inventor: Sebastian Beck Joergensen
  • Patent number: 11260176
    Abstract: An autoinjector (100?) for expelling a single dose of a drug from a held cartridge (600) comprising a piston (630). The autoinjector includes a needle shield (350, 380?) axially movable from an initial extended position via a triggering position to a trigger release position. The needle shield (350, 380?) is operatively coupled to a plunger release element (320?, 1320) cooperating with a plunger (310, 400) to define a releasable retaining mechanism that retains the plunger release element (320?, 1320) threadedly engaged with a base thread component (204?, 1204) in a predefined relative rotational and axial position and against rotational bias provided by an actuator (330). The needle shield (350, 380?) is configured for operating the retaining mechanism to release the retaining of the plunger release element (320?, 1320) and the base thread component (204?, 1204) from the predefined relative rotational and axial position upon the needle shield (350, 380?) being moved into the trigger release position.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: March 1, 2022
    Assignee: Novo Nordisk A/S
    Inventor: Soeren Kjellerup Hansen
  • Publication number: 20220047678
    Abstract: The present disclosure relates to a method of treating non-alcoholic steatohepatitis (NASH) comprising administering to a subject with NASH a combination therapy comprising semaglutide, firsocostat, and/or cilofexor.
    Type: Application
    Filed: June 3, 2021
    Publication date: February 17, 2022
    Applicants: Gilead Sciences, Inc., Novo Nordisk A/S
    Inventors: Constantine Stephen Djedjos, Bryan John McColgan, Robert Paul Myers, Gangadharan Mani Subramanian, Lene Melchiorsen, Morten Hansen